RAND Report Recommends Case-Control Ephedra Study Look At AE Risk
This article was originally published in The Tan Sheet
A case-control study examining the risk of serious adverse events related to the use of ephedra and ephedrine alkaloid-containing dietary supplements would fill a vital gap in the current body of research on the supplement ingredient, the RAND report states
You may also be interested in...
NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act
Recent comments by Paul Shekelle, MD/PhD and RAND Corp. colleagues represent "a dramatic departure from the objective, peer-reviewed findings of the RAND report" on ephedra, according to Ephedra Education Council General Counsel Wes Siegner
Statements that adverse event reports are not sufficient on their own to establish causality, "while technically true, are not an adequate reflection of current scientific standards for adverse event assessment," FDA states